To verify that WNT/β-catenin pathway inhibitor can block the activation of ADMSC-Exos on WNT pathway in wound healing, a total of 9 male SD rats (270 ~ 290 g) were randomly divided into blank control group, XAV939 group, ADMSC-Exos treatment group and ADMSC-Exos + XAV939 (ADMSC-Exos + X) treatment group. The wound model was made in the same way as above. On day 1, day 5, and day 10 after injury, the ADMSC-Exos treatment group was injected with 100 μg exosome locally around the wound, and the ADMSC-Exos + XAV939 treatment group was injected with the same amount of exosome locally around the wound. XAV939 treatment group and ADMSC-Exos + X treatment group were intraperitoneally injected XAV939 (# M1796, AbMole, USA) four times on day 1, each time 1.25 mg/kg. XAV939 selectively inhibite downstream β-catenin in the WNT pathway. The control group was not treated. The wound healing of each group was recorded by camera on day 0, day 3, day 7, and day 14, and the wound area was calculated by Image-Pro Plus 6.0 software. The rats were sacrificed on the 14th day after surgery for H&E staining, Masson staining and immunohistochemical analysis.
Xav939
Manufactured by AbMole
Sourced in United States
XAV939 is a small molecule that inhibits the Wnt/β-catenin signaling pathway. It functions by directly binding to and inhibiting the activity of the tankyrase enzymes, which are involved in the regulation of β-catenin stability.
Automatically generated - may contain errors
Lab products found in correlation
Essential 8 medium, by Thermo Fisher Scientific (2 mentions)
Tryple select, by Thermo Fisher Scientific (2 mentions)
Stemflex medium, by Thermo Fisher Scientific (2 mentions)
Essential 8, by Thermo Fisher Scientific (2 mentions)
Revitacell supplement, by Thermo Fisher Scientific (2 mentions)
Iwp l6, by AbMole (2 mentions)
Chir99021, by Axon Medchem (2 mentions)
Lithium chloride (licl), by Merck Group (1 mentions)
4 protocols using xav939
1
Inhibition of WNT/β-Catenin Pathway in Wound Healing
2
Cardiomyocyte Differentiation of hiPSCs
3
Modulation of Lung Cell Cultures
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A normal bronchial epithelial cell line (HBE) was derived from Shanghai Ysribio Industrial Co., Ltd. Human lung adenocarcinoma adjacent normal cells and human lung cancer cell lines PC9, H1650, H1299, and H446 were all from the First Affiliated Hospital of Nanchang University. The sources of cells used in this study have obtained the informed consent of patients and the approval of the First Affiliated Hospital of Nanchang University Ethics Committee.
All the cells and cell lines were cultured in the medium supplemented with 10% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin and cultured in an incubator at 37°C and 5% CO2. The cells were multiplied to a certain number for reserve use.
A549 cells in a logarithmic growth phase were seeded into 96-well plates and then added a pathway inhibitor (XAV939) (AbMole, US) or agonist (LiCl) (Sigma-Aldrich, Merck) to induce culture.
All the cells and cell lines were cultured in the medium supplemented with 10% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin and cultured in an incubator at 37°C and 5% CO2. The cells were multiplied to a certain number for reserve use.
A549 cells in a logarithmic growth phase were seeded into 96-well plates and then added a pathway inhibitor (XAV939) (AbMole, US) or agonist (LiCl) (Sigma-Aldrich, Merck) to induce culture.
4
Cardiomyocyte Differentiation of hiPSCs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Subclones from two control hiPSC lines (LUMC0020iCTRL (Zhang et al., 2014 (link)) [LUMC20]; LUMC0099iCTRL [LUMC99]), and two hiPSC lines derived from patients diagnosed with HCM (LUMC0033iMyBPC [HCM1]; LUMC0035iMyBPC [HCM3] (Birket et al., 2015 (link))) were maintained either in Essential 8 or StemFlex Medium (both Gibco). One day prior to differentiation (d-1), the hiPSCs were harvested using TrypLE Select (Gibco) and plated onto Matrigel-coated wells of a 12-well cell culture plate, either in Essential 8 Medium containing RevitaCell Supplement (1:200 dilution; Gibco) or StemFlex Medium at 3.9 × 104/cm2. The hiPSCs were differentiated into cardiomyocytes either using the Pluricyte Cardiomyocyte Differentiation Kit (NCardia) according to the manufacturer's instructions, or in a modified BPEL medium (Elliott et al., 2011 (link)) supplemented with small molecules. Specifically, 5 μM CHIR99021 (Axon Medchem) from day 0 to day 2 of differentiation and 5 μM XAV939 + 0.25 μM IWP-L6 (AbMole) from differentiation day 2 to day 4. The hiPSC-CMs were maintained in Medium C (NCardia) until differentiation day 20–21 (LUMC20 and LUMC99), or the modified BPEL medium until differentiation day 14 or 17 (HCM1 and HCM3), and then dissociated as previously described (van den Berg et al., 2014 ).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!